Lipocine Inc.
LPCNNasdaq
$2.23
↓ -2.6%Jul 17 close · end-of-day
Price
1Y↓ -29.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.2M
Enterprise Value
-$9.6M
P/E
—
P/S
7.6
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.0M
Net Income (TTM)
-$11.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-605.9%
Net Margin
-571.2%
ROE
-50.1%
ROIC
—
Debt / Equity
—
Net Cash
$24.7M
Return 1Y
-29.6%
Company profile
Lipocine focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
- CEO
- Mahesh V. Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- United States
- Website
- lipocine.com
Earnings
LPCN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$119,397.00↑ +27.2%
Diluted EPS-$0.54↑ +54.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $16.1M | $500,000.00 | -$2.9M | $11.2M | $2.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.0M | $3.1M | -$12.1M | -$17.9M | -$1.2M | -$10.4M |
| Net income | -$21.0M | -$634,399.00 | -$10.8M | -$16.4M | $10,000.00 | -$9.6M |
| Diluted EPS | -$0.38 | -$0.01 | -$2.15 | -$3.14 | — | -$1.69 |
| Operating cash flow | -$15.3M | -$4.4M | -$12.0M | -$11.9M | -$1.2M | -$9.8M |
| Free cash flow | — | -$4.4M | -$12.1M | -$11.9M | -$1.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | 19.5% | -2423.9% | 629.0% | -10.3% | -524.7% |
| Net margin | — | -3.9% | -2151.7% | 573.5% | 0.1% | -487.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $89,565.00 | $0.00 | $3.5M | $93,864.00 | $622,849.00 | $114,574.00 | $1.1M | $119,397.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.3M | -$2.6M | $1.5M | -$2.1M | -$2.4M | -$3.4M | -$2.5M | -$3.8M |
| Net income | -$3.1M | -$2.2M | $1.8M | -$1.9M | -$2.2M | -$3.2M | -$2.4M | -$3.7M |
| Diluted EPS | -$0.56 | -$0.44 | — | -$0.35 | -$0.41 | -$0.59 | -$0.34 | -$0.54 |
| Operating cash flow | -$2.5M | -$2.8M | $1.7M | -$2.0M | -$1.9M | -$3.0M | -$2.9M | -$2.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3676.2% | — | 44.3% | -2226.8% | -386.0% | -2933.5% | -219.6% | -3224.1% |
| Net margin | -3426.2% | — | 51.1% | -1986.8% | -354.1% | -2781.5% | -207.1% | -3075.4% |
Company news
May 18, 2026
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-07 | Higuchi John W. | Buy | 40,000 | $2.03 | $81,200.00 | filing |
| 2026-04-06 | Higuchi John W. | Buy | 123,000 | $2.05 | $252,150.00 | filing |
| 2026-04-06 | Patel Mahesh V.· Chief Executive Officer | Buy | 25,000 | $2.03 | $50,750.00 | filing |
| 2026-04-02 | Patel Mahesh V.· Chief Executive Officer | Buy | 25,000 | $2.02 | $50,500.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.